DOCSLIB.ORG

TIP 45 Detoxification and Substance Abuse Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TIP 45 Detoxification and Substance Abuse Treatment Detoxification and Substance Abuse Treatment A Treatment Improvement Protocol TIP 45 Detoxification and Substance Abuse Treatment A Treatment Improvement Protocol TIP 45 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration 1 Choke Cherry Road Rockville, MD 20857 Acknowledgments Electronic Access and Copies This publication was produced under the of Publication Knowledge Application Program (KAP) con- This publication may be ordered from or down- tract numbers 270-99-7072 and 270-04-7049 loaded from SAMHSA’s Publications Ordering with the Substance Abuse and Mental Health Web page at http://store.samhsa.gov. Or, please Services Administration (SAMHSA), U.S. call SAMHSA at 1-877-SAMHSA-7 (1-877-726- Department of Health and Human Services 4727) (English and Español). (HHS). Andrea Kopstein, Ph.D., M.P.H, Karl D. White, Ed.D, and Christina Currier served as Government Project Officers. Recommended Citation Center for Substance Abuse Treatment. Disclaimer Detoxification and Substance Abuse The views, opinions, and content expressed Treatment. Treatment Improvement Protocol herein are those of the consensus panel and do (TIP) Series, No. 45. HHS Publication No. not necessarily reflect the views, opinions, or (SMA) 15-4131. Rockville, MD: Center for policies of SAMHSA or HHS. No official sup- Substance Abuse Treatment, 2006. port of or endorsement by SAMHSA or HHS for these opinions or for particular instru- ments, software, or resources is intended or Originating Office should be inferred. Quality Improvement and Workforce Development Branch, Division of Services Improvement, Center for Substance Abuse Public Domain Notice Treatment, Substance Abuse and Mental All material appearing in this report is in the Health Services Administration, 1 Choke public domain and may be reproduced or Cherry Road, Rockville, MD 20857. copied without permission from SAMHSA. Citation of the source is appreciated. However, HHS Publication No. (SMA) 15-4131 this publication may not be reproduced or dis- Printed 2006 tributed for a fee without the specific, written Revised 2008, 2012, 2013, and 2015 authorization of the Office of Communications, SAMHSA, HHS. ii Acknowledgments Contents What Is a TIP?........................................................................................................vii Consensus Panel ......................................................................................................ix KAP Expert Panel and Federal Government Participants ................................................xi Foreword ..............................................................................................................xiii Executive Summary .................................................................................................xv Chapter 1—Overview, Essential Concepts, and Definitions in Detoxification........................1 Purpose of the TIP.....................................................................................................1 Audience..................................................................................................................2 Scope ......................................................................................................................2 History of Detoxification Services...................................................................................2 Definitions................................................................................................................3 Guiding Principles in Detoxification and Substance Abuse Treatment .....................................7 Challenges to Providing Effective Detoxification ................................................................8 Chapter 2—Settings, Levels of Care, and Patient Placement...........................................11 Role of Various Settings in the Delivery of Services ...........................................................11 Other Concerns Regarding Levels of Care and Placement...................................................20 Chapter 3—An Overview of Psychosocial and Biomedical Issues During Detoxification .......23 Evaluating and Addressing Psychosocial and Biomedical Issues ...........................................24 Strategies for Engaging and Retaining Patients in Detoxification ..........................................33 Referrals and Linkages ..............................................................................................38 Chapter 4—Physical Detoxification Services for Withdrawal From Specific Substances .......47 Psychosocial and Biomedical Screening and Assessment .....................................................47 Alcohol Intoxication and Withdrawal.............................................................................52 Opioids ..................................................................................................................66 Benzodiazepines and Other Sedative­Hypnotics ...............................................................74 Stimulants...............................................................................................................76 Inhalants/Solvents.....................................................................................................82 Nicotine..................................................................................................................84 Marijuana and Other Drugs Containing THC ..................................................................95 Anabolic Steroids......................................................................................................96 Club Drugs..............................................................................................................97 Management of Polydrug Abuse: An Integrated Approach.................................................101 Alternative Approaches ............................................................................................103 Considerations for Specific Populations........................................................................105 iii Chapter 5—Co­Occurring Medical and Psychiatric Conditions.......................................121 General Principles of Care for Patients With Co­Occurring Medical Conditions .....................122 Treatment of Co­Occurring Psychiatric Conditions..........................................................136 Standard of Care for Co­Occurring Psychiatric Conditions ...............................................138 Chapter 6—Financing and Organizational Issues .........................................................145 Preparing and Developing a Program...........................................................................145 Working in Today’s Managed Care Environment.............................................................157 Preparing for the Future...........................................................................................168 Appendix A—Bibliography......................................................................................169 Appendix B—Common Drug Intoxication Signs and Withdrawal Symptoms .....................223 Appendix C—Screening and Assessment Instruments ...................................................225 Section I: Screening and Assessment for Alcohol Abuse ....................................................225 Section II: Screening and Assessment for Alcohol and Other Drug Abuse..............................228 Appendix D—Resource Panel..................................................................................231 Appendix E—Field Reviewers..................................................................................233 Index ..................................................................................................................237 SAMHSA TIPs and Publications ...............................................................................243 Figures Figure 1­1 DSM­IV­TR Definitions of Terms .....................................................................6 Figure 1­2 Guiding Principles Recognized by the Consensus Panel .........................................7 Figure 2­1 Issues To Consider in Determining Whether Inpatient or Outpatient Detoxification Is Preferred .......................................................................................21 Figure 3­1 Initial Biomedical and Psychosocial Evaluation Domains......................................25 Figure 3­2 Symptoms and Signs of Conditions That Require Immediate Medical Attention..........26 Figure 3­3 Strategies for De­escalating Aggressive Behaviors ...............................................28 Figure 3­4 Questions To Guide Practitioners To Better Understand the Patient’s Cultural Framework ...........................................................................................................32 Figure 3­5 The Transtheoretical Model (Stages of Change) ..................................................36 Figure 3­6 Clinician’s Characteristics Most Important to the Therapeutic Alliance....................38 Figure 3­7 Recommended Areas for Assessment To Determine Appropriate Rehabilitation Plans...............................................................................................40 Figure 3­8 Strategies To Promote Initiation of Treatment and Maintenance Activities ................42 Figure 4­1 Assessment Instruments for Dependence and Withdrawal From Alcohol and Specific Illicit Drugs................................................................................................49
Load more

Recommended publications
  • Alcohol Intoxication & Intervention Scale
    Alcohol Intoxication & Intervention Scale Alcohol affects each individual differently. The effect of alcohol on a person will vary according to the person's mood, the time of day, Standard Drink amount of food in the stomach, the mixer used, how fast the person One standard drink of beer drinks, and what and why they are drinking. There are a variety of One 12 oz bottle of beer positive and negative consequences related to drinking. One 12 oz can of beer One 8 oz glass of malt liquor (i.e. Blood Alcohol Level Old English, Mickey's) Once you know the definition of one standard drink (see chart to the One standard drink of wine right), you can estimate your Blood Alcohol Level (BAL). BAL levels One 4 oz glass of wine (pictured) represent the percent of your blood that is concentrated with alcohol. A One 3 ‐ 3.5 oz of fortified wine (i.e. BAL of .10 means that .1% of your bloodstream is composed of alcohol. port, sherry) One bottle of table wine is about 5 Some key factors that affect BAL: standard drinks How many standard drinks you drink One standard drink of hard alcohol Remember different drinks have different strengths either One 1.25 oz shot of hard liquor because of differences in proofs of hard liquor or because some (pictured) drinks contain more than one shot One mixed drink containing one 1.25 oz shot of hard liquor Food eaten along with drinking alcohol will result in a lower, One 750ml bottle of hard liquor ("a delayed BAL because the alcohol enters the bloodstream at a fifth") is about 17 standard drinks lower rate Intoxication and Intervention Scale Know the visible signs of intoxication.
    [Show full text]
  • Mapping the Dissociated Body
    Lesley University DigitalCommons@Lesley Graduate School of Arts and Social Sciences Expressive Therapies Capstone Theses (GSASS) Spring 5-16-2020 Mapping the Dissociated Body Elizabeth Hough [email protected] Follow this and additional works at: https://digitalcommons.lesley.edu/expressive_theses Part of the Social and Behavioral Sciences Commons Recommended Citation Hough, Elizabeth, "Mapping the Dissociated Body" (2020). Expressive Therapies Capstone Theses. 239. https://digitalcommons.lesley.edu/expressive_theses/239 This Thesis is brought to you for free and open access by the Graduate School of Arts and Social Sciences (GSASS) at DigitalCommons@Lesley. It has been accepted for inclusion in Expressive Therapies Capstone Theses by an authorized administrator of DigitalCommons@Lesley. For more information, please contact [email protected], [email protected]. Running Head: MAPPING THE DISSOCIATED BODY 1 Mapping the Dissociated Body Elizabeth Hough Lesley University Running Head: MAPPING THE DISSOCIATED BODY 2 Abstract This capstone thesis explored the use of body mapping and body scans as a tool for assessing and tracking somatic dissociation and embodiment. The researcher utilized a client- centered approach and mindfulness-based interventions and theory to ground the work with the clients. While there were a variety of questionnaire-based tools for assessing dissociation with clients, many of them were lacking in the somatic component of dissociation. The available assessments were also exclusively self-reported and written or verbal, which had the potential to result in biased reporting. Clients may have also struggled to identify their level of somatic dissociation due to an inherent disconnection or dismissal of their somatic experience. This research described two case studies in which body scans and body mapping were utilized as a method to assess and track the client’s level of body dissociation and embodiment.
    [Show full text]
  • Addiction Stigma Language- the Words We Use Matter
    naabt.org The National Alliance of Advocates for Buprenorphine Treatment The Words We Use Matter. Reducing Stigma through Language. Why does language matter? Stigma remains the biggest barrier to addiction treatment faced by patients. Changing the stigma will benefit everyone. It will allow patients to The terminology used to describe addiction has contributed to the stigma. more easily regain their self esteem, allow lawmakers to appropriate Many derogatory, stigmatizing terms were championed throughout the “War funding, allow doctors to treat without disapproval of their peers, allow on Drugs” in an effort to dissuade people from misusing substances. Education insurers to cover treatment, and help the public understand this is a took a backseat, mainly because little was known about the science of medical condition as real as any other. addiction. That has changed, and the language of addiction medicine should be changed to reflect today’s greater understanding. By choosing language Choosing the words we use more carefully is one way we can all make that is not stigmatizing, we can begin to dismantle the negative stereotype a difference and help decrease the stigma. associated with addiction. “…In discussing substance use disorders, words can be powerful when used to inform, clarify, encourage, support, enlighten, and unify. On the other hand, stigmatizing words often discourage, isolate, misinform, shame, and embarrass…” Excerpt from “Substance Use Disorders: A Guide to the Use of Language” published by CSAT and SAMHSA Words to avoid and alternatives. Following are stigmatizing words and phrases which could be replaced Habit or Drug Habit with the suggested “preferred terminology” as a start in reducing the Problem with the terms: Calling addictive disorders a habit denies stigma associated with addiction.
    [Show full text]
  • Nottinghamshire Primary Care Alcohol Misuse Guidelines
    Nottinghamshire Primary Care Alcohol Dependence Guidelines V5.2 Last reviewed: April Review date: August 2021 2022 Title Nottinghamshire Primary Care Alcohol Dependence Guidelines Version 5.2 Lead - Dr Stephen Willott, GP Windmill Practice, Nottingham; Clinical Lead for alcohol misuse, Nottingham Recovery Network and Public Health Department, Nottingham City Council Author / Tanya Behrendt, Senior Pharmacist (Nottingham City Locality), NHS Nottingham and Nottinghamshire CCG Nominated Apollos Clifton-Brown, Operational Manager, Nottingham Recovery Network Dr David Rhinds, Consultant Addictions Psychiatrist, Nottinghamshire Healthcare NHS Foundation Trust Lead Dr Kaanthan Jawahar, ST6 Old Age Psychiatry, Derbyshire Healthcare NHS Foundation Trust Hannah Godden, Mental Health Interface and Efficiencies Pharmacist, Nottinghamshire Healthcare NHS Foundation Trust/ NHS Nottingham and Nottinghamshire CCG Jill Theobald, Interface Efficiencies Pharmacist, NHS Nottingham and Nottinghamshire CCG Approval Date August 2019 Review Date August 2022 Section Contents Page Number i. Summary 2 1. Introduction 4 2. Scope 5 3. Aims of Community Detoxification 5 4. Identifying suitable patients 5 5. Medical risks of community detoxification 6 6. Risk reduction 6 7. Record keeping 7 8. Equipment 7 9. Preparation for home detoxification 7 10. Medication 8 11. Relapse prevention/Follow up 8 12. Reducing alcohol consumption in people with alcohol dependence 9 13. Potentially difficult situations 10 14. References and version control 10 Appendix A Diagnostic Criteria
    [Show full text]
  • Alcohol Intoxication Withdrawal Adult
    Provincial Clinical Knowledge Topic Alcohol Intoxication Withdrawal, Adult Emergency Department V 1.5 © 2018, Alberta Health Services. This work is licensed under the Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. Disclaimer: This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use. Document History Version Date Description of Revision Completed By / Revised By 1.1 July 2015 Completed document (2013) reformatted into Dr. Bullard / Carla new topic template Milligan 1.2 January Minor edits in the Rationale section and form 1 Dr. Bullard / Sarah 2016 info in general care section as well as addition Searle of CIWA-Ar Scoring Reference tool to appendix 1.3 May 2016 Minor edits made to working group Sarah Searle membership list 1.4 June Removed link to Center for Addiction and Dr. Bullard / Sarah 2017 Mental Health assessment and documentation Searle form on pg. 35. Documentation requirements will continue as per local practice at this time.
    [Show full text]
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Benzodiazepine & Alcohol Co-Ingestion
    The Journal of COLLEGIATE EMERGENCY MEDICAL SERVICES ISSN: 2576-3687 (Print) 2576-3695 (Online) Journal Website: https://www.collegeems.com Benzodiazepine & Alcohol Co-Ingestion: Implications for Collegiate-Based Emergency Medical Services David Goroff & Alexander Farinelli Keywords: alcohol, benzodiazepines, collegiate-based emergency medical services, toxicology Citation (AMA Style): Goroff D, Farinelli A. Benzodiazepine and Alcohol Co-In- gestion. J Coll Emerg Med Serv. 2018; 1(2): 19-23. https://doi.org/10.30542/ JCEMS.2018.01.02.04 Electronic Link: https://doi.org/10.30542/JCEMS.2018.01.02.04 Published Online: August 8, 2018 Published in Print: August 13, 2018 (Volume 1: Issue 2) Copyright: © 2018 Goroff & Farinelli. This is an OPEN ACCESS article distributed under the terms of the Creative Commons Attribu- tion 4.0 International (CC BY 4.0) License, which permits unrestrict- ed use, distribution, and reproduction in any medium, provided the original author and source are credited. The full license is available at: https://creativecommons.org/licenses/by/4.0/ CLINICAL REVIEW Benzodiazepine & Alcohol Co-Ingestion: Implications for Collegiate-Based Emergency Medical Services David Goroff, MS, NRP & Alexander Farinelli, BS, NRP ABSTRACT KEYWORDS: alcohol, The co-ingestion of benzodiazepines and alcohol presents a unique challenge to colle- benzodiazepines, collegiate- giate EMS providers, due to the pharmacological interaction of the two substances and based emergency medical the variable patient presentations. Given the likelihood that collegiate EMS providers services, toxicology will be called to treat a patient who has co-ingested benzodiazepines and alcohol, this Corresponding Author and review discusses the relevant pharmacology, clinical presentation, and treatment of these Author Affiliations:Listed co-ingestion patients.
    [Show full text]
  • Addiction and Substance Abuse in Anesthesiology Ethan O
    Ⅵ REVIEW ARTICLES David S. Warner, M.D., and Mark A. Warner, M.D., Editors Anesthesiology 2008; 109:905–17 Copyright © 2008, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Addiction and Substance Abuse in Anesthesiology Ethan O. Bryson, M.D.,* Jeffrey H. Silverstein, M.D.† Despite substantial advances in our understanding of addic- idents, and 19% reported at least one pretreatment tion and the technology and therapeutic approaches used to fatality.2 Substantial advances have occurred in our fight this disease, addiction still remains a major issue in the understanding of addiction as well as both the tech- anesthesia workplace, and outcomes have not appreciably changed. Although alcoholism and other forms of impair- nology and therapeutic approaches used to fight this ment, such as addiction to other substances and mental ill- disease, although outcomes have not appreciably ness, impact anesthesiologists at rates similar to those in changed. Starting with a brief review of the basic other professions, as recently as 2005, the drug of choice for concepts of addiction, this article highlights the cur- anesthesiologists entering treatment was still an opioid. rent thoughts regarding the pathophysiologic basis of There exists a considerable association between chemical dependence and other psychopathology, and successful addiction, as well as clinical manifestations, legal is- treatment for addiction is less likely when comorbid psycho- sues, and treatment strategies. pathology is not treated. Individuals under evaluation or Anesthesiologists (as well as any physician) may suffer treatment for substance abuse should have an evaluation from addiction to any number of substances, though with subsequent management of comorbid psychiatric con- addiction to opioids remains the most common.
    [Show full text]
  • A User's Guide to Methamphetamine
    A USER’S GUIDE TO METHAMPHETAMINE A self-help guide to reduce harm for people who use methamphetamine 1st Edition, March 2017 Acknowledgements This booklet was adapted from an original publication created by The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. This information does not constitute medical advice. Please seek the immediate help of a qualified medical practitioner about any personal health concerns. This booklet is being distributed for information purposes only. In the current state of crisis related to crystal methamphetamine, this booklet is intended as a guide to reduce harm for people who use methamphetamine. It lists the most common features of methamphetamine use, ways to reduce harm associated with the use of meth, and strategies for cutting down and quitting. The best way to avoid problems with drugs is to not use them. We are grateful for the contributions of the Integrated Drug Strategies in Waterloo Region and Guelph Wellington, in particular the leadership of Adrienne Crowder and Lindsay Sprague. Don Roth, Kerry Manthenga, Shirley Hilton, and our community review team provided great support and helpful edits. Marcey Gray provided exemplary skill on the design, images and editing, with final expert assistance from Arkay Design and Print. We are thankful for the financial support to print copies from the Waterloo-Wellington Human Services and Justice Coordinating Committee. For more information please contact: Wellington Guelph Drug Strategy www.wgdrugstrategy.ca Waterloo Region Integrated Drugs Strategy www.waterlooregiondrugstrategy.ca Circulated with the support of: WaterlooRegion Integrated Drugs Strategy WaterlooRegion Integrated Drugs Strategy The best way to avoid problems with drugs is to not use them.
    [Show full text]
  • Diazepam and Kava Combination Article
    Journal of Advanced Research (2014) 5, 587–594 Cairo University Journal of Advanced Research ORIGINAL ARTICLE Enhanced efficacy and reduced side effects of diazepam by kava combination Rasha A. Tawfiq a, Noha N. Nassar b,*, Wafaa I. El-Eraky c, Ezzeldein S. El-Denshary b a Egyptian Patent Office, Academy of Scientific Research and Technology, 101 Kasr El-Eini St., Cairo, Egypt b Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Eini St., Cairo, Egypt c Department of Pharmacology, National Research Center, El-Tahrir St., Giza, Egypt ARTICLE INFO ABSTRACT Article history: The long term use of antiepileptic drugs possesses many unwanted effects; thus, new safe com- Received 2 April 2013 binations are urgently mandated. Hence, the present study aimed to investigate the anticonvul- Received in revised form 18 July 2013 sant effect of kava alone or in combination with a synthetic anticonvulsant drug, diazepam Accepted 15 August 2013 (DZ). To this end, female Wistar rats were divided into two subsets, each comprising 6 groups Available online 22 August 2013 as follows: group (i) received 1% Tween 80 p.o. and served as control, while groups (ii) and (iii) received kava at two dose levels (100 and 200 mg/kg, p.o.). The remaining three groups received Keywords: (iv) DZ alone (10 mg/kg p.o.) or kava in combination with DZ (v) (5 mg/kg, p.o.) or (vi) (10 mg/ Kava kg, p.o.). Results of the present study revealed that kava increased the maximal electroshock Diazepam seizure threshold (MEST) and enhanced the anticonvulsant effect of diazepam following both Anticonvulsant acute and chronic treatment.
    [Show full text]
  • XELJANZ (Tofacitinib)
    HIGHLIGHTS OF PRESCRIBING INFORMATION Psoriatic Arthritis (in combination with nonbiologic DMARDs) These highlights do not include all the information needed to use XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. (2.2) XELJANZ/XELJANZ XR safely and effectively. See full prescribing Recommended dosage in patients with moderate and severe renal information for XELJANZ. impairment or moderate hepatic impairment is XELJANZ 5 mg once daily. (2, 8.7, 8.8) ® XELJANZ (tofacitinib) tablets, for oral use Ulcerative Colitis ® XELJANZ XR (tofacitinib) extended-release tablets, for oral use XELJANZ 10 mg twice daily for at least 8 weeks; then 5 or 10 mg Initial U.S. Approval: 2012 twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to WARNING: SERIOUS INFECTIONS AND MALIGNANCY maintain response. (2.3) See full prescribing information for complete boxed warning. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment: half the total daily dosage Serious infections leading to hospitalization or death, including recommended for patients with normal renal and hepatic function. (2, 8.7, tuberculosis and bacterial, invasive fungal, viral, and other 8.8) opportunistic infections, have occurred in patients receiving Dosage Adjustment XELJANZ. (5.1) See the full prescribing information for dosage adjustments by indication If a serious infection develops, interrupt XELJANZ/XELJANZ XR for patients receiving CYP2C19 and/or CYP3A4 inhibitors; in patients until the infection is controlled. (5.1) with moderate or severe renal impairment or moderate hepatic Prior to starting XELJANZ/XELJANZ XR, perform a test for latent impairment; and patients with lymphopenia, neutropenia, or anemia.
    [Show full text]